Immunocompromised patients and COVID infections: Who's at risk? Early in the pandemic, clinicians noticed that certain immunocompromised patients were experiencing persistent SARS-CoV-2 infections, some lasting weeks to months at a time. Science X Medical Xpress

...

COVID and beyond: labs unite to boost genomic surveillance globally Two laboratories in Britain and South Africa, which were at the forefront of tracking new coronavirus variants during the pandemic, have teamed up to keep the focus on genomic surveillance globally as the COVID emergency recedes. Jennifer Rigby Reuters

...

South America dengue spike prompts vaccination drive as bug spray runs out | Reuters

World risks missing deadline for pandemic accord, says WHO chief

COVID-19 infection in pregnancy may raise baby's risk of respiratory illness - UPI.com Babies born to COVID-infected mothers have triple the risk of developing a breathing disorder that normally affects preemies, a new study shows. UPI

...

Researchers found that exposure to the coronavirus while in the womb increased a newborn's risk of respiratory distress syndrome by sparking an "inflammatory cascade" in the infants that affected their breathing. 

...

Study: Vaccinated patients have lower risk of long COVID At 90-days post-infection, 8% of vaccinated cases were still reporting symptoms, compared with 27% of unvaccinated cases. CIDRAP

Today researchers from the University of Michigan published in Open Forum Infectious Diseases more evidence that being vaccinated against COVID-19 significantly reduces the risk of developing long COVID.

...

WHO grants emergency listing for Corbevax COVID vaccine Non-exclusive licensing of the yeast strain by developers will allow others to develop effective, low-cost vaccines. CIDRAP

The World Health Organization (WHO) has approved another COVID-19 vaccine for emergency use listing (EUL): Corbevax, a recombinant protein–based vaccine developed by scientists at Texas Children's Hospital and Baylor College of Medicine.